A study of BRAF V600E mutant colorectal cancer using advanced tests
Part of Cancer, Digestive system clinical trials.
This trial is researching colorectal cancer that has a specific genetic change called BRAF V600E. It uses advanced testing (multi-omics) to learn more about the cancer and find better ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer confirmed by a biopsy or other tissue test.
- Your tumor must have a specific gene change called BRAF V600E, found through genetic testing.
- You must be 18 years or older.
- You cannot have had more than two previous types of systemic cancer treatment (like chemotherapy or targeted therapy).
- You cannot have serious heart disease, uncontrolled high blood pressure, bleeding in the brain, or serious lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
Hear when a new BRAF V600E-mutant Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.